PCSK9 and atherosclerosis: Studies evaluating preclinical models show that PCSK9-inhibitor treatment leads to the regression of inflammation and early atherosclerosis biomarkers, mostly via interfering with the nf-κB factor and eNOS pathways, as well as monocyte adhesion to endothelial cells [83].